drugset / Trial / NCT05298332

Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects

NCT05298332

Phase 1 Terminated 37 enrolled Antios Therapeutics, Inc
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a single center, open-label, 3-Cohort, parallel, single-dose, study to evaluate the PK, safety, and tolerability of ATI-2173 50 mg administered orally in Japanese, Chinese, and Non-Asian healthy subjects incorporating a food effect analysis in Non-Asian healthy subjects.

Timeline

Start
2022-03-29
Primary completion
2022-08-22
Completion
2022-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject FOSCLEVUDINE ALAFENAMIDE Other / unclassified 50 mg Oral